Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein production for vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming second quarter 2024 financial results release and corporate update conference call. The event is scheduled for Tuesday, August 13, 2024, at 5:00 p.m. Eastern Time.
Investors and interested parties can access the call via toll-free (877-407-0784) or international (+1-201-689-8560) numbers, using the Conference ID: 13743569. A webcast will also be available, with an archive accessible on Dyadic's Investor Relations website within 24 hours after the live event. Participants are encouraged to submit questions for the Q&A session via email to ir@dyadic.com prior to the call.
Dyadic International, Inc. (NASDAQ: DYAI), un'azienda biotecnologica specializzata nella produzione di proteine su larga scala per vaccini, terapie e applicazioni non farmaceutiche, ha annunciato la prossima pubblicazione dei risultati finanziari del secondo trimestre 2024 e della conferenza di aggiornamento aziendale. L'evento è programmato per martedì 13 agosto 2024, alle 17:00, ora orientale.
Investitori e parti interessate possono accedere alla chiamata attraverso il numero verde (877-407-0784) o numeri internazionali (+1-201-689-8560), utilizzando l'ID della conferenza: 13743569. Sarà disponibile anche una trasmissione in diretta, con un archivio accessibile sul sito web delle Relazioni con gli Investitori di Dyadic entro 24 ore dopo l'evento dal vivo. Si incoraggiano i partecipanti a inviare domande per la sessione di domande e risposte via email a ir@dyadic.com prima della chiamata.
Dyadic International, Inc. (NASDAQ: DYAI), una empresa biotecnológica especializada en la producción a gran escala de proteínas para vacunas, terapias y aplicaciones no farmacéuticas, ha anunciado la próxima publicación de los resultados financieros del segundo trimestre de 2024 y la conferencia de actualización corporativa. El evento está programado para martes 13 de agosto de 2024, a las 5:00 p.m., hora del Este.
Los inversores y partes interesadas pueden acceder a la llamada a través del número gratuito (877-407-0784) o números internacionales (+1-201-689-8560), utilizando el ID de conferencia: 13743569. También estará disponible una transmisión web, con un archivo accesible en el sitio web de Relaciones con Inversores de Dyadic dentro de las 24 horas posteriores al evento en vivo. Se anima a los participantes a enviar preguntas para la sesión de preguntas y respuestas por correo electrónico a ir@dyadic.com antes de la llamada.
다이아딕 인터내셔널 주식회사 (NASDAQ: DYAI)는 백신, 치료제 및 비약물 응용을 위한 대규모 단백질 생산을 전문으로 하는 생명공학 회사로, 2024년 2분기 재무 결과 발표 및 기업 업데이트 컨퍼런스 콜을 예정하고 있다고 발표했습니다. 이 행사는 2024년 8월 13일 화요일 오후 5시 동부 표준시로 예정되어 있습니다.
투자자 및 관심 있는 분들은 수신 무료 전화 (877-407-0784) 또는 국제 전화 (+1-201-689-8560)를 통해 콜에 접속할 수 있으며, 콘퍼런스 ID: 13743569를 사용해야 합니다. 또한 웹캐스트가 제공되며, 라이브 이벤트 후 24시간 이내에 다이아딕 투자자 관계 웹사이트에서 아카이브를 볼 수 있습니다. 참가자들은 콜 전에 ir@dyadic.com으로 이메일을 통해 Q&A 세션에 대한 질문을 제출하도록 권장됩니다.
Dyadic International, Inc. (NASDAQ: DYAI), une entreprise biotechnologique spécialisée dans la production de protéines à grande échelle pour les vaccins, les thérapies et les applications non pharmaceutiques, a annoncé la prochaine publication de ses résultats financiers pour le deuxième trimestre 2024 et la conférence de mise à jour des entreprises. L'événement est prévu pour mardi 13 août 2024, à 17h00, heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder à l'appel via le numéro sans frais (877-407-0784) ou des numéros internationaux (+1-201-689-8560), en utilisant l'ID de conférence : 13743569. Un webinaire sera également disponible, avec un enregistrement accessible sur le site des Relations Investisseurs de Dyadic dans les 24 heures suivant l'événement en direct. Les participants sont encouragés à soumettre des questions pour la session de questions-réponses par email à ir@dyadic.com avant l'appel.
Dyadic International, Inc. (NASDAQ: DYAI), ein biotechnologisches Unternehmen, das sich auf die großflächige Proteinproduktion für Impfstoffe, Therapien und nicht-pharmazeutische Anwendungen spezialisiert hat, hat die bevorstehende Veröffentlichung der Finanzberichte des zweiten Quartals 2024 und die Unternehmensupdate-Konferenz bekannt gegeben. Die Veranstaltung ist für Dienstag, den 13. August 2024, um 17:00 Uhr Eastern Time angesetzt.
Investoren und Interessierte können den Anruf über die gebührenfreie Nummer (877-407-0784) oder internationale Nummern (+1-201-689-8560) erreichen und den Konferenz-ID: 13743569 verwenden. Ein Webcast wird ebenfalls verfügbar sein, mit einem Archiv, das innerhalb von 24 Stunden nach der Live-Veranstaltung auf der Investor-Relations-Website von Dyadic zugänglich ist. Die Teilnehmer werden ermutigt, ihre Fragen für die Q&A-Sitzung per E-Mail an ir@dyadic.com vor dem Anruf zu senden.
- None.
- None.
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, August 13, 2024.
Conference Call Information:
Date: Tuesday, August 13, 2024
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560
Conference ID: 13743569
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1650832&tp_key=276447f116. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email ir@dyadic.com prior to the conference call.
About Dyadic International, Inc.
Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the issuance of Convertible Notes and the use of proceeds thereof. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ
When will Dyadic (DYAI) report its Q2 2024 financial results?
What time is Dyadic's (DYAI) Q2 2024 earnings call scheduled for?
How can investors access Dyadic's (DYAI) Q2 2024 earnings call?
Where can I find the webcast for Dyadic's (DYAI) Q2 2024 earnings call?
How long after the live event will the webcast archive be available for Dyadic's (DYAI) Q2 2024 earnings call?
